$11.90
-0.09-0.75%
Last update: Nov 12, 10:58 AM
NovoCure Ltd (NVCR) Stock Price, Quote, News & History
NVCRNASDAQ
Novocure receives an FDA Not Approvable Letter for Optune Mya in NSCLC brain metastases, citing unclear clinical benefit while finding no safety issues.
You can purchase shares of NovoCure (NASDAQ:NVCR) through any online brokerage.
Other companies in NovoCure’s space includes: Abbott Laboratories (NYSE:ABT), Intuitive Surgical Inc (NASDAQ:ISRG), Medtronic PLC (NYSE:MDT), Stryker Corp (NYSE:SYK) and Boston Scientific Corp (NYSE:BSX).
NovoCure has a consensus price target of $26.86.
The stock price for NovoCure (NASDAQ: NVCR) is $11.9 last updated November 12, 2026 at 10:58 AM EST.
There are no upcoming dividends for NovoCure.
NovoCure does not have any upcoming earnings scheduled.
There is no upcoming split for NovoCure.
NovoCure is in the Health Care sector and Health Care Equipment & Supplies industry. They are listed on the NASDAQ.
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune...
